Clarity Pharmaceuticals Ltd (cu6) Logo

Clarity Pharmaceuticals Ltd (CU6)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Message Icon
New Company Lists are coming! Which ones do you want? - Click here for 1-question survey 😊

CU6 Chart

Snapshot

CU6's Principal Activity is the clarity is a clinical stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -27.88%

Size

Market Capitalisation
ASX Rank 687 of 2,296
Sector Rank -

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies -
EPS $0.00
DPS $0.00
NTA per share $0.00

Broker Consensus

CU6 is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Corporate Overview

Clarity Pharmaceuticals Ltd (CU6) is a clinical stage radiopharmaceutical company. The company is a global leader in Targeted Copper Theranostics (TCT), developed with their proprietary SAR Technology platform. The group also has a range of products in clinical trials which address both prostate cancer and breast cancer as well as neuroendocrine tumours (NETs) and neuroblastoma of cancer.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Eveleigh NSW 2015
Website www.claritypharmaceuticals.com
Registry Link Market Services
Auditor Grant Thornton Audit Pty Ltd
Date Listed 25 Aug 2021

Upcoming Calendar (Forecasted)

Date Event
24/08/2022 Report (Prelim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Robert Bain Thomas Non-Executive Director Aug 2021 Director Bio icon

Mr Robert Bain Thomas

Non-Executive Director

Mr Thomas has a background in financial services and capital markets and has experience in mergers & acquisitions and capital markets including advising on the IPOs of the Commonwealth Bank of Australia and Qantas. Mr Thomas is the former CEO of County NatWest Securities and the former CEO (and then Chairman) of Citi Corporate and Investment Bank Australasia. Mr Thomas has also held the position of Chairman at Australian Wealth Management Ltd (ultimately IOOF Ltd), TAL (Australia's largest life insurance company) and the previously ASX-listed company HeartWare International Inc. Mr Thomas is the Chairman of AusBio Ltd, Grahger Retail Securities Pty Ltd and ASX-listed Starpharma Holdings Limited, and is a non-executive director of Biotron Limited and O'Connell Street Associates. He is a past non-executive director of Reva Medical Inc. and Virgin Australia. He is also served as chair of Risk Committee of CU6.

Dr Colin David Biggin Chief Executive Officer,Managing Director Oct 2019 Director Bio icon

Dr Colin David Biggin

Chief Executive Officer,Managing Director

Dr Biggin has over 15 years of radiopharmaceutical development and commercialisation experience. Dr Biggin previously served with Algeta ASA during the development and commercialisation of its product Xofigo (radium-223 dichloride) for metastatic prostate cancer, which was approved by the FDA in 2013. Prior to joining the Company, Dr Biggin also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals.

Dr Charles Gillies O'Bryan-Tear Non-Executive Director Apr 2019 Director Bio icon

Dr Charles Gillies O'Bryan-Tear

Non-Executive Director

Dr O'Bryan-Tear has over 30 years of experience in the pharmaceutical industry in clinical development, medical management and commercial roles. He has held senior leadership roles in large and small pharmaceutical and biotech companies in the US and Europe and has been involved in multiple product approvals. He was previously the Chief Medical Officer of Algeta ASA. Dr O'Bryan-Tear has been an adviser to several US and European biotech companies and is a member of the Scientific Advisory Boards of Audentes, Inc. (US) and Fusion Pharmaceuticals Inc. (Canada).

Dr Thomas Ramdahl Non-Executive Director Mar 2019 Director Bio icon

Dr Thomas Ramdahl

Non-Executive Director

Dr Ramdahl is a pharmaceutical executive with over 20 years of clinical and development experience. In 2001, he became President and the first CEO of Algeta ASA. When Dr Ramdahl joined Algeta, he was one of six employees and he was involved in serving in several senior positions within the company through to and post the acquisition of Algeta by Bayer AG in 2014. Dr Ramdahl has authored more than 40 publications and is a co-inventor of several patents. Dr Ramdahl currently serves as Chairman of Precirix (Belgium) and AppSens AS (Norway).

Dr Christopher Graham Roberts Non-Executive Director Mar 2016 Director Bio icon

Dr Christopher Graham Roberts

Non-Executive Director

Dr Roberts has over 40 years of experience in the medical innovation space and has served on the boards of a number of ASX-listed companies during his career. Dr Roberts was previously the CEO of ASX-listed company Cochlear Limited and Chairman of ASX-listed company Sirtex Medical Ltd. Dr Roberts was also Executive VicePresident and a director of the dual-listed (ASX and NYSE) company ResMed Inc., a global sleep disorder treatment company. Dr Roberts is Chairman of the ASX-listed company Oncosil Ltd. He is also served as member of Risk Committee of CU6.

Dr Alan John Taylor Executive Chairman,Executive Director Nov 2013 Director Bio icon

Dr Alan John Taylor

Executive Chairman,Executive Director

Dr Taylor has approximately 15 years of investment banking experience focused mainly on the life sciences sector, and also has experience in capital raisings, mergers and acquisitions, and general corporate advisory. Prior to joining Clarity, Dr Taylor was an Executive Director of Inteq Limited, a boutique Australian investment bank.

Ms Rosanne Elizabeth Robinson Non-Executive Director Oct 2010 Director Bio icon

Ms Rosanne Elizabeth Robinson

Non-Executive Director

Ms Robinson has experience in the nuclear field and has over 25 years of experience in both governance and management roles in public and private companies and government. Ms Robinson is the General Manager of Business Development at Australian Nuclear Science and Technology Organization. Ms Robinson also has experience of the nuclear medicine industry and knowledge of most recent changes in the sector. She is also served as member of Risk Committee of CU6.

Mr Robert Cochrane Vickery Chief Financial Officer,Company Secretary N/A

Director Interests

The current holdings of CU6 directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Robert Thomas 25/08/2021 550,000 475,000 N/A N/A
Colin Biggin 01/10/2019 419,100 N/A 5,600,000 N/A
Charles O'Bryan-Tear 03/04/2019 N/A N/A 900,000 N/A
Thomas Ramdahl 26/03/2019 N/A N/A 600,000 N/A
Christopher Roberts 24/03/2016 N/A 17,911,280 200,000 N/A
Alan Taylor 28/11/2013 N/A 14,066,660 2,800,000 N/A
Rosanne Robinson 19/10/2010 N/A N/A 200,000 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Aug 23, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
TM Ventures Pty Ltd 18,788,460 7.34%
Cabbit Pty Ltd 17,911,280 6.99%
Genesiscare Ventures 15,362,700 6.00%
A.C.N. 136 437 913 Pty Ltd 13,266,660 5.18%
Charles Waite Morgan 12,330,220 4.81%
HSBC Custody Nominees (Australia) Limited (i) 10,669,568 4.17%
National Nominees Limited 8,020,161 3.13%
Boorris Pty Ltd 7,815,800 3.05%
Vantres Pty Ltd 7,487,340 2.92%
Yarrawah Pty Ltd 6,752,859 2.64%
Firetrail Investments Pty Ltd 6,000,000 2.34%
Moore Family Nominee Pty Ltd 5,800,000 2.26%
Hat Investments Atf Hunter Angels Trust No 1 5,599,180 2.19%
Smarter Capital Pty Ltd 5,500,000 2.15%
Citicorp Nominees Pty Limited 5,187,176 2.03%
Kylaco Pty Ltd 3,896,280 1.52%
UBS Nominees Pty Ltd 3,648,150 1.42%
Australian Nuclear Science & Technology Organisation 3,599,920 1.41%
HSBC Custody Nominees (Australia) Limited (ii) 3,571,429 1.39%
CS Third Nominees Pty Limited 3,500,000 1.37%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 7 174 155 355 165 856

Substantial Shareholders

No Substantial Shareholders for CU6 in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
25-08-21 Charles Waite Morgan 18,593,040 -- 7.26
25-08-21 Alan John Taylor 14,066,660 -- 5.49
25-08-21 Matthew John Harris 14,078,620 -- 5.50
25-08-21 Cabbit Pty Ltd 17,911,280 -- 6.99
25-08-21 Genesis Care Pty Limited 15,362,700 -- 6.00
25-08-21 TM Ventures Pty Ltd 18,788,460 -- 7.34

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
Page Icon
CU6 Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.